Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk

STAT·Apr 1

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

The FDA has approved an obesity pill from Eli Lilly, which is expected to compete with a similar product from Novo Nordisk. This approval sets up a competitive battle between the two companies in the weight loss drug market. The pill, a GLP-1 medication, has been shown to maintain weight loss similar to injectable GLP-1 treatments.

Full coverage

LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?

qz.com·8h ago

FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

BioPharma Dive·Apr 1

Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk

Reuters·Apr 1

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market

CNBC·Apr 1

Lilly's weight-loss pill wins US approval; sets up next battle with rival Novo Nordisk

The Detroit News·Apr 1

Updated: Lilly wins FDA approval of anti-obesity pill orforglipron, setting up new battle with Novo

Endpoints News·Apr 2

Oral Obesity Drug Battle Is On with FDA OK for Lilly’s Orforglipron

DCAT Value Chain Insights·Apr 2

Lilly's obesity pill largely maintains weight lost on injectable GLP-1s

Fierce Biotech·Dec 18

View original report at STAT ↗

Fetching the latest headlines…